Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al

A recent meta-analysis of randomized clinical trials reported by Bongartz and coworkers raised concerns about an increased rate of malignancy and serious infection in rheumatoid arthritis patients treated with anti-tumour necrosis factor monoclonal antibodies. This commentary discusses some of the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Dixon, Will, Silman, Alan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779433/
https://www.ncbi.nlm.nih.gov/pubmed/16911768
http://dx.doi.org/10.1186/ar2026
_version_ 1782131770342244352
author Dixon, Will
Silman, Alan
author_facet Dixon, Will
Silman, Alan
author_sort Dixon, Will
collection PubMed
description A recent meta-analysis of randomized clinical trials reported by Bongartz and coworkers raised concerns about an increased rate of malignancy and serious infection in rheumatoid arthritis patients treated with anti-tumour necrosis factor monoclonal antibodies. This commentary discusses some of the methodological issues in their analysis and urges caution in interpreting the results.
format Text
id pubmed-1779433
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-17794332007-01-19 Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al Dixon, Will Silman, Alan Arthritis Res Ther Commentary A recent meta-analysis of randomized clinical trials reported by Bongartz and coworkers raised concerns about an increased rate of malignancy and serious infection in rheumatoid arthritis patients treated with anti-tumour necrosis factor monoclonal antibodies. This commentary discusses some of the methodological issues in their analysis and urges caution in interpreting the results. BioMed Central 2006 2006-08-11 /pmc/articles/PMC1779433/ /pubmed/16911768 http://dx.doi.org/10.1186/ar2026 Text en Copyright © 2006 BioMed Central Ltd
spellingShingle Commentary
Dixon, Will
Silman, Alan
Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al
title Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al
title_full Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al
title_fullStr Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al
title_full_unstemmed Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al
title_short Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al
title_sort is there an association between anti-tnf monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? commentary on the meta-analysis by bongartz et al
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779433/
https://www.ncbi.nlm.nih.gov/pubmed/16911768
http://dx.doi.org/10.1186/ar2026
work_keys_str_mv AT dixonwill isthereanassociationbetweenantitnfmonoclonalantibodytherapyinrheumatoidarthritisandriskofmalignancyandseriousinfectioncommentaryonthemetaanalysisbybongartzetal
AT silmanalan isthereanassociationbetweenantitnfmonoclonalantibodytherapyinrheumatoidarthritisandriskofmalignancyandseriousinfectioncommentaryonthemetaanalysisbybongartzetal

Ejemplares similares